Cargando…
肺癌免疫治疗耐药机制及应对策略
Inhibition of immune checkpoints is at the forefront of immunotherapy for lung cancer. However, a high percentage of lung cancer patients do not respond to these immunotherpy or their responses are transient, indicating the existence of immune resistance. Emerging evidence suggested that the interac...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936078/ https://www.ncbi.nlm.nih.gov/pubmed/33626853 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.02 |
Ejemplares similares
-
非小细胞肺癌免疫耐药机制及应对策略的研究进展
por: JING, Yawan, et al.
Publicado: (2023) -
Venetoclax在慢性淋巴细胞白血病中的耐药机制及治疗策略
Publicado: (2020) -
酪氨酸激酶抑制剂耐药机制及其治疗策略
Publicado: (2011) -
BCMA-CAR-T细胞治疗多发性骨髓瘤后复发与耐药的机制及防治策略
Publicado: (2021) -
复发/难治性非霍奇金淋巴瘤CAR-T细胞治疗后的复发机制及应对策略
Publicado: (2020)